Diastolic Dysfunction of Aging Is Independent of Myocardial Structure but Associated with Plasma Advanced Glycation End-Product Levels

Duncan J. Campbell1,2*, Jithendra B. Somaratne3, Alicia J. Jenkins2, David L. Prior2,3, Michael Yii4,5, James F. Kenny5, Andrew E. Newcomb4,5, Casper G. Schalkwijk6, Mary Jane Black7, Darren J. Kelly2

1 St. Vincent’s Institute of Medical Research, Fitzroy, Australia, 2 Department of Medicine, The University of Melbourne, St. Vincent’s Health, Fitzroy, Australia, 3 Department of Cardiology, St. Vincent’s Health, Fitzroy, Australia, 4 Department of Surgery, University of Melbourne, St. Vincent’s Health, Fitzroy, Australia, 5 Department of Cardiothoracic Surgery, St. Vincent’s Health, Fitzroy, Australia, 6 Department of Internal Medicine, University of Maastricht, Maastricht, The Netherlands, 7 Department of Anatomy and Developmental Biology, Monash University, Clayton, Australia

Abstract

**Background:** Heart failure is associated with abnormalities of myocardial structure, and plasma levels of the advanced glycation end-product (AGE) N^ε-(carboxymethyl)lysine (CML) correlate with the severity and prognosis of heart failure. Aging is associated with diastolic dysfunction and increased risk of heart failure, and we investigated the hypothesis that diastolic dysfunction of aging humans is associated with altered myocardial structure and plasma AGE levels.

**Methods:** We performed histological analysis of non-ischemic left ventricular myocardial biopsies and measured plasma levels of the AGEs CML and low molecular weight fluorophores (LMWFs) in 26 men undergoing coronary artery bypass graft surgery who had transthoracic echocardiography before surgery. None had previous cardiac surgery, myocardial infarction, atrial fibrillation, or heart failure.

**Results:** The patients were aged 43–78 years and increasing age was associated with echocardiographic indices of diastolic dysfunction, with higher mitral Doppler flow velocity A wave (r = 0.50, P = 0.02), lower mitral E/A wave ratio (r = 0.64, P = 0.001), longer mitral valve deceleration time (r = 0.42, P = 0.03) and lower early diastolic peak velocity of the mitral septal annulus, e’ (r = 0.55, P = 0.008). However, neither mitral E/A ratio nor mitral septal e’ was correlated with myocardial total, interstitial or perivascular fibrosis (picrosirius red), immunostaining for collagens I and III, CML, and receptor for AGEs (RAGE), cardiomyocyte width, capillary length density, diffusion radius or arteriolar dimensions. Plasma AGE levels were not associated with age. However, plasma CML levels were associated with E/A ratio (r = 0.44, P = 0.04) and e’ (r = 0.51, P = 0.02) and LMWF levels were associated with E/A ratio (r = 0.49, P = 0.02). Moreover, the mitral E/A ratio remained correlated with plasma LMWF levels in all patients (P = 0.04) and the mitral septal e’ remained correlated with plasma CML levels in non-diabetic patients (P = 0.007) when age was a covariate.

**Conclusions:** Diastolic dysfunction of aging was independent of myocardial structure but was associated with plasma AGE levels.

---

Introduction

Aging is accompanied by increased vascular and ventricular stiffness, diastolic dysfunction and an increased risk of heart failure [1–4]. Heart failure, with either reduced or preserved ejection fraction, is associated with abnormalities of myocardial structure and microvasculature including increased fibrosis, cardiomyocyte hypertrophy and reduced microvascular density [5–9], and animal models suggest that these abnormalities precede the development of heart failure in older age. Senescent animals have reduced cardiomyocyte number, hypertrophy of surviving cardiomyocytes, increased cardiac fibrosis, reduced capillary density and increased diffusion radius [10–13]. In addition, advanced glycation end-products (AGEs) are proposed to contribute to the increased myocardial stiffening of aging by cross-linking collagen and elastin and promoting collagen accumulation [14], and by promoting inflammation and oxidative stress mediated by the receptor for AGEs (RAGE) [15]. Moreover, plasma AGE levels correlate with...
Table 1. Clinical, biochemical and hemodynamic characteristics of men undergoing coronary artery bypass graft surgery who had transthoracic echocardiography before surgery.

| Characteristic                                      | Mean ± SEM or n (%) | n = 26 |
|-----------------------------------------------------|---------------------|-------|
| Mean age (years)                                    | 65 ± 2              |       |
| Left main stenosis >50%, n (%)                      | 14 (54%)            |       |
| One vessel stenosis >70%, n (%)                     | 4 (15%)             |       |
| Two vessel stenosis >70%, n (%)                     | 16 (62%)            |       |
| Three vessel stenosis >70%, n (%)                   | 6 (23%)             |       |
| Patients with occluded coronary artery, n (%)       | 10 (38%)            |       |
| Coronary collaterals, Rentrop grade 2 or 3, n (%)   | 13 (50%)            |       |
| Previous percutaneous transluminal coronary angioplasty, n (%) | 4 (15%)            |       |
| Wall motion abnormality, n (%)                      | 3 (12%)             |       |
| Coronary grafts/patient (n)                         | 3.3 ± 0.2           |       |
| Body mass index (kg/m²)                             | 29.0 ± 0.9          |       |
| Body surface area (m²)                              | 2.01 ± 0.03         |       |
| Clinical risk factors                               |                     |       |
| Diabetes, n (%)                                     | 6 (23%)             |       |
| Metabolic syndrome (non-diabetic), n (%)            | 14 (54%)            |       |
| Pre-admission systolic blood pressure (mmHg)        | 134 ± 2             |       |
| Pre-admission diastolic blood pressure (mmHg)       | 78 ± 1              |       |
| Pre-admission pulse pressure (mmHg)                 | 56 ± 2              |       |
| Previous hypertension, n (%)                        | 17 (65%)            |       |
| Use of tobacco, ever, n (%)                         | 17 (65%)            |       |
| Fasting plasma total cholesterol (mmol/L)           | 3.5 ± 0.2           |       |
| Fasting plasma LDL cholesterol (mmol/L)             | 2.0 ± 0.2           |       |
| Fasting plasma HDL cholesterol (mmol/L)             | 0.91 ± 0.04         |       |
| Fasting plasma triglyceride (mmol/L)                | 1.6 ± 0.2           |       |
| Fasting plasma glucose (mmol/L)                     | 6.5 ± 0.3           |       |
| Fasting plasma insulin (pmol/L)                     | 57 ± 11             |       |
| ß cell function from HOMA2-%B                        | 83 ± 9              |       |
| Insulin sensitivity from HOMA2-%S                    | 93 ± 13             |       |
| Insulin resistance from HOMA2-IR                    | 1.6 ± 0.2           |       |
| Plasma CML (µmol/L)                                 | 2.1 ± 0.1           |       |
| Plasma LMWF (AU/mL)                                 | 2.7 ± 0.2           |       |
| Plasma soluble RAGE (pg/mL)                         | 698 ± 63            |       |
| Plasma NT-proBNP (pmol/L)                           | 15 ± 2              |       |
| Hemoglobin (g/L)                                    | 14.1 ± 0.3          |       |
| Plasma creatinine (µmol/L)                          | 95 ± 3              |       |
| eGFR (mL/min per 1.73 m²)                           | 72 ± 3              |       |
| C-reactive protein (mg/L)                           | 4.7 ± 1.4           |       |
| Medications                                          |                     |       |
| ACE inhibitor therapy, n (%)                        | 13 (50%)            |       |
| ARB therapy, n (%)                                  | 7 (27%)             |       |
| ACEI and/or ARB therapy, n (%)                      | 20 (77%)            |       |
| Statin therapy, n (%)                               | 23 (88%)            |       |
| Aspirin therapy, n (%)                              | 24 (92%)            |       |
| Calcium antagonist therapy, n (%)                   | 5 (19%)             |       |
| ß-blocker therapy, n (%)                            | 16 (62%)            |       |
| Long-acting nitrate therapy, n (%)                  | 5 (19%)             |       |
| Thiazide or indapamide therapy, n (%)               | 2 (8%)              |       |

Intra-operative hemodynamics immediately post induction of anesthesia
Table 1. Cont.

| Characteristic                              | Mean±SEM or n (%)       |
|---------------------------------------------|-------------------------|
| Central venous pressure (mmHg)              | 8.6±0.9                 |
| Pulmonary capillary wedge pressure (mmHg)   | 10.3±0.7                |
| Cardiac index (L/min/m²)                    | 2.7±0.2                 |
| Stroke Volume index (mL/m²)                 | 47±2                    |

Coronary collaterals were scored according to Rentrop et al. [58]. ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate calculated using the Modification of Diet in Renal Disease study equation [30]; CML, Nε-(carboxymethyl)lysine; HDL, high density lipoprotein; HOMA, Homeostasis Model Assessment calculator version 2.2 [31]; LDL, low density lipoprotein; LMWF, low molecular weight fluorophore; NT-proBNP, amino-terminal-pro-B-type natriuretic peptide; RAGE, receptor for advanced glycation end-products.

doi:10.1371/journal.pone.0049813.t001

Figure 1. Correlations between echocardiographic parameters and age in men with coronary artery disease. Age was not correlated with mitral Doppler flow velocity E wave velocity (A), but was correlated with mitral Doppler flow velocity A wave velocity (B), E/A ratio (C), mitral early inflow deceleration time (D) and mitral early diastolic peak velocity of the septal mitral annulus, e’ (E). However, the correlation of age with E/e’ ratio was not statistically significant (F).

doi:10.1371/journal.pone.0049813.g001
the severity and prognosis of heart failure and predict all-cause and cardiovascular disease mortality in older adults [16,17]. There is, however, only limited information about the effects of aging on the structure and microvasculature of the human myocardium, which comes mainly from autopsy studies that may have been influenced by comorbidities [18–20]. We investigated the hypothesis that diastolic dysfunction of aging humans is associated with altered myocardial structure and plasma AGE levels. We performed histological analysis of non-ischemic left ventricular (LV) myocardial biopsies from patients without heart failure or previous myocardial infarction who were undergoing coronary artery bypass graft surgery and had transthoracic echocardiography before surgery. We measured total, interstitial and perivascular myocardial fibrosis, cardiomyocyte size, capillary length density, diffusion radius and arteriolar dimensions. We also measured myocardial expression of the AGE N\(^\text{ε}\)-(carboxymethyl)lysine (CML) and RAGE, and plasma levels of CML, low molecular weight fluorophores (LMWFs) and soluble RAGE. Although we obtained LV biopsies from both men and women, preliminary analysis showed gender-specific differences in myocardial structure [21]; therefore, given the smaller number of women recruited to this study, the present analysis was confined to men. We previously reported that neither diabetes nor the metabolic syndrome was associated with altered myocardial total or interstitial fibrosis, cardiomyocyte width, capillary length density, diffusion radius, arteriolar dimensions or immunostaining for collagens I and III, CML, or RAGE in this patient population, although diabetic and metabolic syndrome patients had reduced perivascular fibrosis [22].

Methods

The St. Vincent’s Health Human Research Ethics Committee (Fitzroy, Australia) approved the study protocol. Each participant provided written informed consent to be included in the study.

Patients

Details of the Cardiac Tissue Bank have been previously described [21–23]. From the Tissue Bank we selected all of 26 male patients having coronary artery bypass graft surgery alone who had transthoracic echocardiography before surgery; none had heart failure or atrial fibrillation, had received loop diuretic therapy or had evidence of previous myocardial infarction. Absence of previous myocardial infarction was established from the clinical history, electrocardiogram and troponin measurements, and was confirmed by inspection of the ventriculogram, transthoracic and transesophageal echocardiography and examination of the heart at surgery. All patients had normal or near-normal LV systolic function as assessed by pre-operative transthoracic echocardiography and ventriculogram, with LV ejection fraction ≥50%. A partial-thickness wedge-shaped biopsy was taken during surgery, immediately after cardioplegia, from a region of the lateral wall of the LV near the base of the heart, between the territories of the left anterior descending and circumflex arteries, that was free of any macroscopic pathology, without evidence of ischemia or wall motion abnormality on pre-operative or intra-operative imaging studies.

The metabolic syndrome was defined according to the International Diabetes Federation [24]. For patients in whom abdominal circumference was not measured, based on the relationship between abdominal circumference and BMI [25], those with BMI ≥25 kg/m\(^2\) were considered to exceed the abdominal circumference threshold for the metabolic syndrome. A patient had diabetes if a history of diabetes was evident from use of glucose-lowering medications and/or insulin or if fasting plasma glucose was ≥7 mmol/L [26]. All 6 diabetic patients had type 2 diabetes; one was newly diagnosed and treated with diet alone, two were treated with insulin alone, one with insulin and metformin, and two with metformin and glitazide. The mean duration of diabetes was 13 (range 0–30) years and the mean HbA1c was 7.5% (range 5.3–9.8%, n = 5).

Preoperative Transthoracic Echocardiography and Intra-operative Hemodynamics

Preoperative transthoracic echocardiography was performed and reported by either the referring institution or by St. Vincent’s Health according to the American Society of Echocardiography guidelines [27]. Left ventricular mass was calculated using the Devereux equation and left ventricular mass index was calculated by dividing left ventricular mass by height\(^2\cdot7\) [28,29]. All patients...
had Swan-Ganz catheters inserted before surgery that provided measures of pulmonary artery and pulmonary capillary wedge pressures and cardiac output recorded immediately after induction of anesthesia.

Biochemistry

Blood hemoglobin and hemoglobin A1c and plasma levels of creatinine were measured as part of the routine pre-surgery workup. All other variables were measured on fasting blood collected on the day of surgery, before induction of anesthesia. Estimated glomerular filtration rate (eGFR) was calculated from the Modification of Diet in Renal Disease formula [30]. Insulin resistance (HOMA2-IR), insulin sensitivity (HOMA2-%S) and β-cell function (HOMA2-%B) were calculated using the HOMA calculator version 2.2 [31]. CML was measured by ELISA (Microcoat, Penzberg, Germany). LMWFs were measured by fluorescence spectroscopy [32]. Soluble RAGE was measured by electrochemiluminescence immunoassay using an Elecsys instrument (Roche Diagnostics, Basel, Switzerland).

Histological Analysis

Details of tissue collection, fixation and histology have been previously described [21–23]. All histological analyses were performed blind to patient identity and age. Picosirius red-
stained 4 μm sections of paraffin-embedded tissue were analyzed for total, interstitial and perivascular fibrosis and arteriolar dimensions by quantitative morphometry of digitized images of the whole myocardial section (Aperio Technologies, Inc., CA) as previously described [21–23]. Myocardial total fibrosis was calculated using the positive pixel count algorithm (Aperio Technologies, Inc., CA) as the area of collagen staining expressed as a percentage of the total myocardial tissue area, after excluding the pericardium. Immunohistochemistry for CML was performed in paraffin sections using a mouse monoclonal antibody as described by Schalkwijk et al. [39]. Immunohistochemistry for RAGE was performed with goat polyclonal antibody AB5484 (Millipore, Billerica, MA). Immunostaining of arteriolar media and intima for CML and of arteriolar media, intima and capillaries for RAGE was individually scored by its intensity as 0+, 1+, 2+, or 3+, after inspection of the digitized image of the whole of each section.

Statistical Analysis
Data are shown as means±SEM or n (%). Correlations were estimated using Pearson correlation coefficients and were considered significant at P<0.05.

Results
Study Patients
The clinical, biochemical and hemodynamic characteristics of the study patients (age range 43–78 years) are shown in Table 1. Older age was associated with increased plasma NT-proBNP levels (P=0.001) and reduced eGFR (P=0.03). The extent of coronary artery disease (proportions of patients with left main stenosis, three-vessel stenosis, occluded coronary arteries, coronary collaterals and wall motion abnormalities) and number of bypass grafts performed were unrelated to age. In addition, diabetes, metabolic syndrome, medication use and hemodynamics, including pulmonary capillary wedge pressure, were not associated with age.

Echocardiography
Age was not associated with LV ejection fraction, left atrial dimensions, LV mass (not shown) or mitral E wave velocity (Figure 1). However, increasing age was associated echocardiographic indices of LV diastolic dysfunction, with higher mitral Doppler flow velocity A wave, lower E/A wave ratio, longer mitral valve deceleration time, and lower early diastolic peak velocity of the mitral septal annulus, e′, although the association between age and E/e′ ratio did not achieve statistical significance (Figure 1). None of the echocardiographic parameters was associated with the presence of wall motion abnormalities or with pulse pressure.
Histology

Given that the strongest correlations between age and echocardiographic indices of diastolic dysfunction were for mitral E/A ratio and mitral septal e’ velocity, we examined the correlation between these echocardiographic parameters and myocardial histology.

The area of myocardial paraffin sections (median 4.3 mm², 1.7–10.6 mm²) was unrelated to patient age. Myocardial total, interstitial and perivascular fibrosis were not associated with either mitral E/A ratio or mitral septal e’ velocity (Figure 2 and 3). In addition, myocardial total collagen I and III immunostaining were not associated with mitral E/A ratio or mitral septal e’ velocity, although these echocardiographic parameters were weakly associated with collagen I/collagen III ratio (Figure 4 and 5).

Cardiomyocyte width, capillary length density, diffusion radius (not shown) and arteriolar wall area/circumference ratio were not associated with either mitral E/A ratio or mitral septal e’ velocity (Figure 6).

Immunostaining for CML was predominantly localized to the media and intima of arterioles and venules, whereas RAGE immunostaining was predominantly localized to the intima of arterioles and venules and to capillaries (Figure 7). Neither CML immunostaining of arteriolar media and intima nor RAGE immunostaining of arteriolar media, intima and capillaries (not
shown) was associated with mitral E/A ratio or mitral septal e’ velocity (Figure 8 and 9).

Plasma Levels of CML, LMWF and Soluble RAGE

Plasma CML levels were not statistically significantly correlated with age in either all patients ($r=0.21$, $P=0.30$, $n=26$) or non-diabetic patients ($r=0.30$, $P=0.20$, $n=20$). Similarly, plasma LMWF levels were not statistically significantly correlated with age in either all patients ($r=0.25$, $P=0.22$, $n=26$) or non-diabetic patients ($r=0.28$, $P=0.23$, $n=20$). There were, however, significant correlations between plasma levels of CML and LMWFs and echocardiographic indices of diastolic dysfunction (Figure 10). In multivariate analysis with age as a covariate, the standardized coefficients for the correlations between CML, LMWFs and diastolic dysfunction were closer to zero and many were no longer statistically significant, indicating that the association of these AGEs with diastolic dysfunction was dependent in part on their weak, though not statistically significant, correlation with age (Table 2). There was also evidence that the correlation between plasma AGEs and diastolic dysfunction was in part independent of age in that the mitral E/A ratio remained significantly correlated with plasma LMWF levels in all patients, and the mitral septal e’ velocity (Figure 6).

Figure 6. Correlations between cardiomyocyte width, capillary length density and arteriolar wall area/circumference ratio and echocardiographic parameters of diastolic dysfunction, mitral E/A ratio and mitral septal e’ velocity, in men with coronary artery disease. Cardiomyocyte width, capillary length density and arteriolar wall area/circumference ratio were not correlated with mitral E/A ratio (A, B, C) or with mitral septal e’ velocity (D, E, F).

doi:10.1371/journal.pone.0049813.g006
velocity remained significantly correlated with plasma CML levels in non-diabetic patients when age was a covariate (Table 2). Plasma levels of soluble RAGE did not correlate with any echocardiographic parameter or with eGFR or pulse pressure (not shown).

Discussion

The key finding of this study was that the diastolic dysfunction of aging men undergoing coronary artery bypass graft surgery was not associated with myocardial fibrosis or alteration in cardiomyocyte width, capillary length density, diffusion radius, arteriolar dimensions or myocardial expression of CML and RAGE, but was associated with plasma levels of CML and LMWFs, and these associations were dependent, in part, on age. In addition to diastolic dysfunction, older patients had higher plasma NT-proBNP levels and lower eGFR, consistent with the effects of aging. Our patient population included men with type 2 diabetes and the metabolic syndrome, and in a separate analysis we showed that neither condition affected myocardial structure, microvasculature, or expression of CML and RAGE, apart from reduced perivascular fibrosis of diabetic and metabolic syndrome patients [22]. Although diabetic patients showed evidence of impaired diastolic function [22], the association between plasma AGE levels and diastolic dysfunction in the present study remained after exclusion of diabetic patients. Our findings suggest that the increased myocardial fibrosis, cardiomyocyte hypertrophy and reduced microvascular density of heart failure patients [5–9] are a consequence, rather than an initiating cause, of heart failure in the elderly and, in addition, that mechanisms other than alteration in myocardial structure and microvasculature contribute to the diastolic dysfunction of aging.

Echocardiographic indices of diastolic dysfunction are associated with an increased risk of heart failure [40]. Our finding that age was associated with echocardiographic indices of diastolic dysfunction but not with pulmonary capillary wedge pressure was in agreement with previous studies reporting that although associated with alterations with LV filling, age is not associated with invasive measures of pulmonary capillary wedge pressure or with LV isovolumic pressure decay [41–43]. Many different mechanisms other than alteration in myocardial structure and microvasculature may contribute to alterations in LV filling and increased heart failure risk of aging individuals [2,3,44], including alteration in myocardial energetics. Both myocardial phosphore-
atine/adenosine triphosphate ratio and diastolic function are influenced by physical activity status [45], and myocardial phosphocreatine/adenosine triphosphate ratio is reported to be negatively correlated with age [4,46]. A failure to detect a correlation between age and myocardial phosphocreatine/adenosine triphosphate ratio in other studies may be because of the limited age range of the subjects studied [45,47,48]. However, myocardial phosphocreatine/adenosine triphosphate ratio was unrelated to the changes in diastolic function that occur with normal human aging [4,46]. Other potential mechanisms of diastolic dysfunction of aging include alteration in titin phosphorylation [49,50], changes in myocardial redox state and impairment of intramyocardial nitric oxide signaling [50,51].

Previous studies reported plasma CML levels were correlated with the severity and prognosis of heart failure [16] and predicted all-cause and cardiovascular disease mortality in older adults [17]. The present study extends this relationship to a much earlier stage in the evolution of heart failure by demonstrating that plasma CML and LMWF levels correlated with diastolic dysfunction in patients without heart failure. The correlation of plasma, but not myocardial, AGE levels with diastolic dysfunction suggests a role for extra-cardiac AGEs in the diastolic dysfunction of aging, such as may result from increased arterial AGE levels causing reduced arterial compliance [52]. In support of this proposal, Semba et al. [53] found an association between plasma CML levels and aortic pulse wave velocity. The AGE cross-link breaker ALT-711 markedly improves arterial compliance in aged canines [52] and in aged humans with vascular stiffening [54]. However, evidence against a direct relationship between arterial compliance and diastolic function was the failure of ALT-711 therapy-induced improvement in arterial compliance to modify LV diastolic properties [52]. Further studies are required to determine the basis of the relationship between plasma AGE levels and diastolic dysfunction. Our finding of a relationship between plasma AGE levels and diastolic dysfunction in older patients without heart failure suggests that plasma AGE levels may serve as a biomarker for the identification of individuals at increased risk of heart failure.

Myocardial RAGE expression was predominantly localized to vascular endothelium and capillaries, in agreement with previous studies [55]. Whereas cell-surface-bound RAGE plays an essential role in mediating the effects of AGEs, soluble RAGE may act as an AGE inhibitor by sequestering AGEs and preventing their binding to the cell-surface-bound RAGE receptor [56]. Our data suggest that neither myocardial RAGE nor plasma soluble RAGE participate in the diastolic dysfunction of aging.

Our study highlights differences between the effects of aging on the myocardium of humans and animals. In contrast to senescent animals [10–13] we found no increase in fibrosis of older patients, in agreement with previous studies in humans [19,57], and no effect of age on capillary length density and diffusion radius, in agreement with the autopsy study of Roberts and Wearn [18]. Moreover, the lack of effect of age on coronary arteriolar dimensions was in agreement with studies of senescent beagles [11]. Our finding of no effect of age on cardiomyocyte size was in agreement with the autopsy study of Roberts and Wearn [18], but

Figure 8. Correlations between N’-(carboxymethyl)lysine (CML) as assessed by immunostaining and echocardiographic parameters of diastolic dysfunction, mitral E/A ratio and mitral septal e’ velocity, in men with coronary artery disease. Immunostaining for CML in arteriolar media and intima was not correlated with mitral E/A ratio (A, B) or with mitral septal e’ velocity (D, E).

doi:10.1371/journal.pone.0049813.g008
was in contrast to other autopsy studies that showed loss of cardiomyocytes and cardiomyocyte hypertrophy in aging men, but not women [19,20].

Our study had a number of limitations. The sample size was limited by the need for myocardial biopsies from each patient, with a possibility of type 2 error; our study was therefore largely limited to univariate analyses and many significant correlations may have been missed. In addition, the exclusion of women limited the generalizability of our findings. As expected for patients undergoing coronary artery bypass graft surgery, all had extensive coronary artery disease. However, patients with coronary artery disease were an important group to study because of the high prevalence of coronary artery disease in the community, and there was no association between extent of coronary artery disease and age in our patient population, suggesting that myocardial ischemia was similar across the different ages. Moreover, Redfield et al. [1] found similar age- and gender-related ventricular-vascular stiffening in patients with and without cardiovascular disease. Twelve percent of our patients had wall motion abnormalities but we found no relationship between the presence of wall motion abnormalities and echocardiographic indices of diastolic dysfunction. We took particular care to collect biopsies from non-ischemic myocardium, although we cannot completely exclude the possibility of myocardial ischemia in the biopsied area. However, we found no impact of coronary disease on myocardial structure and microvasculature in a separate study of patients with aortic stenosis with and without coronary disease [23]. Although left ventricular hypertrophy may impact on diastolic function, we found no association between left ventricular mass or cardiomyocyte width and either mitral E/A ratio or mitral septal e’ velocity. The biopsies were from the same subepicardial region of the LV myocardium in all patients and we do not know if the data obtained apply to other regions of the myocardium.

In summary, we showed that the diastolic dysfunction of aging was independent of myocardial structure and microvasculature, but was associated with plasma AGE levels. Our data therefore suggest that the increased myocardial fibrosis, cardiomyocyte hypertrophy and reduced microvascular density of heart failure patients [5–9] are a consequence, rather than an initiating cause, of heart failure in the elderly and that mechanisms other than alteration in myocardial structure and microvasculature contribute to the diastolic dysfunction of aging. Although further studies are required to determine the basis of their relationship with diastolic dysfunction.
dysfunction, plasma AGE levels may serve as a biomarker to help identify individuals at increased risk of heart failure.

Acknowledgments

We thank Laura Stamp, Robyn Kelly, Kim Hewitt, and Francoise Campbell for assistance with histology.

Author Contributions

Conceived and designed the experiments: DJC JBS AJJ DLP MY JFK AEN CGS MJB DJK. Performed the experiments: DJC AJJ DLP MY JFK AEN MJB. Analyzed the data: DJC AJJ DLP JBS MJB DJK. Contributed reagents/materials/analysis tools: CGS MJB DJK. Wrote the paper: DJC. Revised the manuscript: DJC JBS AJJ DLP MY JFK AEN CGS MJB DJK.

References

1. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA (2005) Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 112: 2254–2262.

2. Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I: Aging arteries: A “set up” for vascular disease. Circulation 107: 139–146.
3. Lakatza EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 107: 346–354.

4. Hollingsworth KG, Blainie AM, Kreavney BD, Maagowan GA (2012) Left ventricular torsion, energetics, and diabetes in normal human adults. Am J Physiol Heart Circ Physiol 302: H883–892.

5. Unverferth DV, Fetters JK, Unverferth BJ, Leier CV, Magorien RD, et al. (1990) Improved collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 81: 1263–1268.

6. Querejeta R, Lopez B, Gonzalez A, Drakos SG, et al. (2008) Determination of the influence of the carboxyethyl derivative of the platelet-derived growth factor in the aging rat heart. Am J Pathol 173: 1473–1488.

7. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, et al. (1992) Assessment of arteriolar and myocardial capillary density in patients with heart failure due to idiopathic dilated cardiomyopathy. J Am Coll Cardiol 22: 1391–1398.

8. van Heerebeek L, Borbeley A, Niessen HW, Bronzea JG, van der Velden J, et al. (2004) Myocyte cell loss and myocyte cellular hyperplasia in the hypertrophied aging rat heart. Circ Res 94: 677–871.

9. Tomancik RJ, Aydelotte MR, Torry RJ (1991) Remodeling of coronary vessels during aging in purified beagles. Circ Res 69: 1068–1074.

10. Anversa P, Li P, Sonnenblick EH, Olivetti G (1994) Effects of aging on myocardial structure and function differ in systolic and diastolic heart failure. Circulation 89: 1163–1173.

11. Tomanek RJ, Aydelotte MR, Torry RJ (1991) Remodeling of coronary vessels during aging in purified beagles. Circ Res 69: 1068–1074.

12. Campbell DJ, Somaratne JB, Jenkins AJ, Prior DL, Yii M, et al. (2011) Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovasc Diabetol 10: 80.

13. van Heerebeek L, Borbeley A, Niessen HW, Bronzea JG, van der Velden J, et al. (2004) Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113: 1966–1973.

14. Tomanek RJ, Aydelotte MR, Torry RJ (1991) Remodeling of coronary vessels during aging in purified beagles. Circ Res 69: 1068–1074.

15. Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L (2009) Plasma retinol-binding protein 4 as a maker of poor physical function in healthy older men and women with coronary artery disease. Hypertension 57: 186–192.

16. Hartog JW, Voors AA, Schalkwijk CG, Scheijen J, Smilde TD, et al. (2007) Plasma low-molecular weight fluorescence in type 1 diabetes mellitus. Ann NY Acad Sci 1043: 655–661.

17. Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L (2009) Plasma retinol-binding protein 4 as a maker of poor physical function in healthy older men and women with coronary artery disease. Hypertension 57: 186–192.

18. Roberts JT, Wearn JT (1941) Quantitative changes in the capillary-muscle relationship in human hearts during normal growth and hypertrophy. Am J Heart Soc 21: 617–633.

19. Olivetti G, Melisaro M, Capasso JM, Anversa P (1991) Cardiomyopathy of the heart of old rats: origin: relation to myocardial fibrosis. Circ Res 67: 330–337.

20. van Heerebeek L, Franssen CP, Hamdani N, Verheugt FW, Somsen GA, et al. (2006) Myocardial structure and function differ in systolic and diastolic heart failure. Am J Physiol Heart Circ Physiol 290: H1260–H1273.

21. Campbell DJ, Somaratne JB, Jenkins AJ, Prior DL, Yii M, et al. (2011) Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovasc Diabetol 10: 80.

22. Van Heerebeek L, Franssen CP, Hamdani N, Verheugt FW, Somsen GA, et al. (2006) Myocardial structure and function differ in systolic and diastolic heart failure. Am J Physiol Heart Circ Physiol 290: H1260–H1273.
56. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA (2011) RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond) 121: 43–55.
57. Unverferth DV, Baker PB, Arn AR, Magorien RD, Fetters J, et al. (1986) Aging of the human myocardium: a histologic study based upon endomyocardial biopsy. Gerontology 32: 241–251.
58. Rentrop KP, Cohen M, Blanke H, Phillips RA (1985) Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 5: 587–592.